How would you manage a patient with morbid obesity who presents with new symptomatic pulmonary embolism a few days after he was started on DOAC for DVT?
How would you manage a patient with morbid obesity who presents with new symptomatic PE a few days after he was started on DOAC for DVT?
Join Mednetto vote and see how they answered.
There are guidelines from the American Society of Hematology and The International Society of Hemostasis and Thrombosis as well as expert opinions recommending either apixaban or rivaroxaban for venous thromboembolism or pulmonary embolism in patients with BMI >40. In addition, this includes use as prophylaxis post-surgical procedures. These conclusions are based on available published clinical data and systemic review/meta-analysis. (Martin et al., PMID 34259389; ASH Clinical News July 2020; Wang and Carrier, PMID 31978224) However, they should not be used after bariatric surgery.
Join for free or sign in to see the full answer
I am comfortable giving DOACs to patients with high BMI based on the data outlined by Dr. @Dr. First Last, unless they have had gastric surgery for weight loss. I would wonder if this "new" PE was actually there at the time of the DVT diagnosis based on older studies that 30%-50% of patients with DVT have asymptomatic PEs at the time of diagnosis (if we imaged them all). I would check APLA though and repeat leg imaging to see if there is evidence of true progression and might do lovenox until I got that information.
Join for free or sign in to see the full answer
Updated answer
I CANNOT assume the DOAC is working. It PROBABLY is, since failure may simply be that a clot has broken off which was going to happen anyway. BUT LET’S BE THOROUGH AND ASSUME THE WORST AS WE SORT THIS OUT. First, check patient compliance. Second, if on Xarelto, be sure the patient is taking it with food. Third, absorption could be an issue so it is best to start LMWH while sorting this out. (Has the patient had a gastric bypass? Specific issues arise in this setting). Fourth, another issue could be at play. Occasionally, patients with aggressive malignancies fail therapy (Trousseau’s). Any symptoms? Weight loss? Bottom line: Data and guidelines suggest DOACs (when taken correctly!) are very effective in morbidly obese. Not a ...
Join for free or sign in to see the full answer
Provided the patient has been receiving rivaroxaban or apixaban, which are the recommended DOACS in patients with BMI >40 according to the ISTH guidelines, and assuming that it has been clearly ascertained that this is a new VTE, I would manage this situation the same way I manage any case of anticoagulation "failure" and switch to a different class of drugs. My preference would be for warfarin after a UFH or LMWH bridge. One could also measure apixaban or rivaroxaban levels to gauge whether proper therapeutic levels have been attained, but these tests are not well standardized and there is an overlap between prophylactic and therapeutic ranges with no validated reference values.
It would also be important to check whether the patient has a...
Join for free or sign in to see the full answer
I would not recommend using DOAC in the obese population, BMI > 35-40, since there is little data on obese patients on DOAC. I would also be concerned that fixed dosing in a morbidly obese patient may have lower drug level and lower efficacy.
Also, I believe the safety data on DOACs, are mostly with patients with non-valvular atrial fibrillation.
Join for free or sign in to see the full answer